{
    "ticker": "CASI",
    "name": "CASI Pharmaceuticals, Inc.",
    "description": "CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer and other serious diseases. Founded in 2010, CASI is headquartered in Rockville, Maryland, USA, and has a strong emphasis on advancing its proprietary pipeline of drug candidates through clinical trials. The company's lead product candidate, ENMD-2076, is a novel oral multi-kinase inhibitor designed to target various cancer pathways, and it is currently being investigated in clinical trials for the treatment of hematological malignancies and solid tumors. CASI also has partnerships and collaborations aimed at enhancing its research capabilities and expanding its product offerings. With a commitment to improving patient outcomes, CASI is dedicated to translating scientific innovation into effective therapies that address unmet medical needs in oncology. The company strives to build a robust portfolio of products that can provide better therapeutic options for patients globally, leveraging its expertise in drug development and regulatory affairs to navigate the complex landscape of the biopharmaceutical industry.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Rockville, Maryland, USA",
    "founded": "2010",
    "website": "https://www.casipharmaceuticals.com",
    "ceo": "James T. Huang",
    "social_media": {
        "twitter": "https://twitter.com/CASIPharma",
        "linkedin": "https://www.linkedin.com/company/casi-pharmaceuticals/"
    },
    "investor_relations": "https://www.casipharmaceuticals.com/investor-relations",
    "key_executives": [
        {
            "name": "James T. Huang",
            "position": "CEO"
        },
        {
            "name": "Hui Zhang",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Products",
            "products": [
                "ENMD-2076"
            ]
        }
    ],
    "seo": {
        "meta_title": "CASI Pharmaceuticals, Inc. | Innovative Cancer Therapeutics",
        "meta_description": "Explore CASI Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative therapies for cancer and serious diseases. Learn about our pipeline and commitment to patient care.",
        "keywords": [
            "CASI Pharmaceuticals",
            "Cancer Treatment",
            "Biopharmaceuticals",
            "ENMD-2076",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What is CASI Pharmaceuticals known for?",
            "answer": "CASI Pharmaceuticals is known for developing innovative cancer therapeutics and its lead product candidate ENMD-2076."
        },
        {
            "question": "Who is the CEO of CASI Pharmaceuticals?",
            "answer": "James T. Huang is the CEO of CASI Pharmaceuticals, Inc."
        },
        {
            "question": "Where is CASI Pharmaceuticals headquartered?",
            "answer": "CASI Pharmaceuticals is headquartered in Rockville, Maryland, USA."
        },
        {
            "question": "What are CASI's main products?",
            "answer": "CASI's main product candidate is ENMD-2076, an oral multi-kinase inhibitor for cancer treatment."
        },
        {
            "question": "When was CASI Pharmaceuticals founded?",
            "answer": "CASI Pharmaceuticals was founded in 2010."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "MRNA",
        "GILD"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "REGN",
        "ABBV"
    ]
}